Healthcare company AmerisourceBergen has partnered with telehealth infrastructure provider SteadyMD to offer a telehealth solution for Test to Treat opportunities to independent community pharmacies across the US. The solution is being offered as a pilot program to expand the number of services that independent pharmacies can provide to patients. The pilot program is being evaluated over a period of 12 weeks and has been launched across 130 independent retail pharmacies. The Test to Treat initiative was initially launched in 2022 to provide equitable access to COVID-19 testing and treatment.
What You Should Know:
- AmerisourceBergen (AB), a global healthcare company, has announced a strategic partnership with SteadyMD, a B2B telehealth infrastructure provider for the co-creation of a telehealth solution focused on Test to Treat opportunities. The solution is being offered as a pilot to independent community pharmacies across the US.
- In addition to the commercial partnership, AmerisourceBergen has also made a minority investment in SteadyMD through its venture fund AB Health Ventures.
Test to Treat Pilot
AmerisourceBergen’s telehealth solution is being developed to expand the number of Test to Treat services that independent pharmacies can offer to patients. The Test to Treat initiative was launched in 2022 to help provide quick and equitable access to COVID-19 testing and treatment in the early days of infection. The model is intended to provide a seamless patient experience and designed to reach high-risk, underserved populations.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
With its telehealth solution, AmerisourceBergen is evaluating the long-term viability of the Test to Treat model for use cases, beyond COVID-19, to improve access to treatment. The pilot program has been launched across a group of 130 independent retail pharmacies, including members of the Good Neighbor Pharmacy network. Over a span of 12 weeks, pilot participants will utilize the SteadyMD platform to provide patients with a quick and accessible Test to Treat option within their pharmacy, at an affordable price. Patients can test for an illness or condition and then, if deemed necessary by a SteadyMD physician, consult with them on demand through the telehealth platform and receive a prescription for treatment.
Pharmacies participating in the telehealth pilot program can use the solution to help patients obtain COVID-19 oral antiviral therapies, as appropriate. AmerisourceBergen and SteadyMD will continuously evaluate opportunities to expand use cases during and after the program.
“The Test to Treat initiative is an important acknowledgement of the role of pharmacists and pharmacies as accessible healthcare providers and destinations,” said Jenni Zilka, Senior Vice President, Good Neighbor Pharmacy Field Programs & Services at AmerisourceBergen. “In order for pharmacies to continue making a sustainable impact on the communities they serve, we need to continue providing them the tools, resources, and authority to provide necessary clinical services, where appropriate. AmerisourceBergen’s exploration of a telehealth solution with SteadyMD to enhance the scope of the Test to Treat model is just one way we’re continuing to support the important role of the pharmacist in the healthcare ecosystem.”
Source: HitConsultant
